We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
-6.2%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.65B
AUM Growth
-$362M
Cap. Flow
-$188M
Cap. Flow %
-11.37%
Top 10 Hldgs %
71.92%
Holding
40
New
3
Increased
6
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$68M
2
ASML icon
ASML
ASML
+$23.3M
3
CBLL
CeriBell Inc
CBLL
+$8.96M
4
MRSN
Mersana Therapeutics
MRSN
+$8.79M
5
ZBIO
Zenas BioPharma
ZBIO
+$7.02M

Top Sells

Rank Stock Value
1
CORT icon
Corcept Therapeutics
CORT
+$112M
2
CABO icon
Cable One
CABO
+$41.4M
3
BN icon
Brookfield
BN
+$39.1M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$32.6M
5
BAM icon
Brookfield Asset Management
BAM
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 55.4%
2 Technology 13.01%
3 Financials 9.73%
4 Consumer Discretionary 2.32%
5 Industrials 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBLL
26
CeriBell Inc
CBLL
$714M
$8.51M 0.52%
+328,809
New +$8.96M
FDMT icon
27
4D Molecular Therapeutics
FDMT
$562M
$8.36M 0.51%
1,500,000
– –
LXEO icon
28
Lexeo Therapeutics
LXEO
$378M
$7.39M 0.45%
1,122,581
– –
KYTX icon
29
Kyverna Therapeutics
KYTX
$484M
$6.92M 0.42%
1,850,000
– –
MRSN
30
DELISTED
Mersana Therapeutics
MRSN
$6.08M 0.37%
+170,000
New +$8.79M
ABCL icon
31
AbCellera Biologics
ABCL
$2.12B
$3.3M 0.2%
1,126,915
– –
IOBT
32
DELISTED
IO Biotech
IOBT
$3.09M 0.19%
3,354,449
– –
MQ icon
33
Marqeta
MQ
$1.66B
$1.67M 0.1%
110,390
– –
DMRA
34
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$465K 0.03%
99,913
– –
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-118,383
Closed -$32.6M
BAM icon
36
Brookfield Asset Management
BAM
$83.8B
– –
-627,207
Closed -$29.7M
CABO icon
37
Cable One
CABO
$212M
– –
-118,403
Closed -$41.4M
CORT icon
38
Corcept Therapeutics
CORT
$12B
– –
-2,411,362
Closed -$112M
SPRO icon
39
Spero Therapeutics
SPRO
$73M
– –
-468,902
Closed -$628K
MGX icon
40
Metagenomi Therapeutics
MGX
$46.3M
– –
-1,800,000
Closed -$3.91M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q4 2024 Portfolio in Review

As of Q4 2024, Novo Holdings A/S held 40 positions worth $1.65B, down 18% from $2.01B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Novo Holdings A/S withdrew a net $188M in Q4 2024, closing 6 positions and reducing 6 holdings. Its most notable exit was Corcept Therapeutics, an estimated $112M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 58% a quarter earlier, followed by Technology and Financials.

Against the trend, Novo Holdings A/S opened a new position in Recursion Pharmaceuticals worth $68.4M.

  • Novo Holdings A/S's largest Q4 2024 buy was Recursion Pharmaceuticals: 10,114,633 shares worth $68.4M.
  • Novo Holdings A/S added most to ASML in Q4 2024, an estimated $23.3M increase.
  • Novo Holdings A/S's biggest Q4 2024 reduction was Brookfield, cutting an estimated $39.1M.
  • Novo Holdings A/S fully exited Corcept Therapeutics in Q4 2024, selling an estimated $112M.
  • Novo Holdings A/S's ten largest holdings make up 72% of its $1.65B portfolio in Q4 2024.
  • Novo Holdings A/S opened 3 new positions and closed 6 in Q4 2024.
  • Novo Holdings A/S's portfolio value fell 18% quarter-over-quarter to $1.65B.

Based on Novo Holdings A/S's 13F filing for Q4 2024, filed 14 Feb 2025.